We then investigated the relevance of NOTCH1 and/or FBXW7 mutations in relation to treatment outcome. For the DCOG cohort, mutations in NOTCH1 and/or FBXW7 tended toward poor treatment outcome. The 5-year EFS rates for patients with NOTCH1 mutations only compared with wild-type patients were 57±8% versus 76±8% (P=0.08) for the DCOG cohort but 63±8 versus 64±10% for the COALL cohort (P=0.99, Figures 3a and b). Inclusion of FBXW7 mutations resulted in 5-year EFS rates of 58±7 versus 74±9% (P=0.16) for the DCOG cohort and 63±8 versus 68±10% for the COALL cohort (P=0.90)...